NCT06877650View on ClinicalTrials.gov

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2029

Conditions
Advanced Malignant Tumors
Interventions
DRUG

JMT108

Intravenous (IV) administration every two weeks (D1, D15) in a 4-week cycle.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY